Literature DB >> 2518725

Mu heavy chains can associate with a pseudo-light chain complex (psi L) in human pre-B cell lines.

W G Kerr1, M D Cooper, L Feng, P D Burrows, L M Hendershot.   

Abstract

In pre-B cells, the earliest identifiable stage of B cell differentiation, there is an asynchrony of immunoglobulin chain expression in that mu heavy chains are synthesized in the absence of light chain synthesis. These mu chains largely remain intracellular and are degraded. Here we demonstrate that a fraction of mu chains in human pre-B cell lines can reach the surface in association with three pre-B-specific proteins with relative molecular masses of 22, 18, and 16 kd, which we term collectively the pseudo-light chain complex, psi L. This association generates a multimeric complex, mu 2-psi L. Two of the psi L proteins (22 and 16 kd) are lambda-immunoreactive and form disulfide bonds with mu chains, suggesting that they are closely related to conventional lambda light chains. The 18 kd psi L species is a non-covalently-associated member of the complex. The expression of mu-psi L complexes on the surface of pre-B cells could have a functional role in the control of pre-B growth and differentiation by the hematopoietic microenvironment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2518725     DOI: 10.1093/intimm/1.4.355

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  26 in total

1.  Fit for life in the immune system? Surrogate L chain tests H chains that test L chains.

Authors:  F Melchers
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  Novel mechanisms control the folding and assembly of lambda5/14.1 and VpreB to produce an intact surrogate light chain.

Authors:  Y Minegishi; L M Hendershot; M E Conley
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

3.  Structure and expression of the human immunoglobulin lambda genes.

Authors:  T J Vasicek; P Leder
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

4.  Peritoneal B cells regulate the numbers of allotype-matched pre-B and B cells in bone marrow.

Authors:  M A Marcos; A Sundblad; E Malenchère; A Coutinho
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

5.  Normal pre-B cells express a receptor complex of mu heavy chains and surrogate light-chain proteins.

Authors:  N Nishimoto; H Kubagawa; T Ohno; G L Gartland; A K Stankovic; M D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

6.  Bone marrow cells in X-linked agammaglobulinemia express pre-B-specific genes (lambda-like and V pre-B) and present immunoglobulin V-D-J gene usage strongly biased to a fetal-like repertoire.

Authors:  M Milili; F Le Deist; G de Saint-Basile; A Fischer; M Fougereau; C Schiff
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

7.  Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development.

Authors:  E Meffre; M Milili; C Blanco-Betancourt; H Antunes; M C Nussenzweig; C Schiff
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

8.  FCRLA is a resident endoplasmic reticulum protein that associates with intracellular Igs, IgM, IgG and IgA.

Authors:  Teresa Santiago; Sergei V Kulemzin; Evdokia S Reshetnikova; Nikolai A Chikaev; Olga Y Volkova; Ludmila V Mechetina; Meina Zhao; Randall S Davis; Alexander V Taranin; Alexander M Najakshin; Linda M Hendershot; Peter D Burrows
Journal:  Int Immunol       Date:  2010-12-13       Impact factor: 4.823

9.  A human non-XLA immunodeficiency disease characterized by blockage of B cell development at an early proB cell stage.

Authors:  E Meffre; F LeDeist; G de Saint-Basile; A Deville; M Fougereau; A Fischer; C Schiff
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

10.  Two types of mu chain complexes are expressed during differentiation from pre-B to mature B cells.

Authors:  T Takemori; J Mizuguchi; I Miyazoe; M Nakanishi; K Shigemoto; H Kimoto; T Shirasawa; N Maruyama; M Taniguchi
Journal:  EMBO J       Date:  1990-08       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.